by Jason Heaviland | Nov 21, 2025
Unlocking FFPE Archives: How TissueBridge™️ Enables Retrospective Profiling of Tumor Metabolism Panome Bio’s TissueBridge technology unlocks the full metabolomic potential of FFPE tissue archives, enabling comprehensive, high-confidence profiling of tumor metabolism...
by Jason Heaviland | Nov 6, 2025
Inside PRMT5: Metabolomics-Driven Insights for Cancer Therapy PRMT5 is a promising therapeutic target, especially in MTAP-deleted tumors, but measuring its inhibition has remained a challenge. In this webinar, Panome Bio scientists introduce a targeted metabolite...
by Jason Heaviland | Oct 29, 2025
Explore Panome Bio’s in-depth proteomics data report profiling global protein expression changes in HCT-116 cells with KRAS knockout. This analysis highlights key signaling pathways and molecular alterations revealed through advanced discovery proteomics analysis,...
by ODWAdmin | Sep 30, 2025
This study from researchers at the University of Arizona utilized Next-Generation Lipidomics from Panome Bio as part of a larger, multi-omic study to find that hypoxia promotes ferroptosis resistance in prostate cancer by altering lipid metabolism at the...
by Jason Heaviland | Sep 25, 2025 | Uncategorized
Why PRMT5 Clinical Trials Need Comprehensive Metabolomic Monitoring Current PRMT5 clinical trials are flying with incomplete instruments. While symmetric dimethylarginine (SDMA) has become the standard pharmacodynamic biomarker for monitoring PRMT5 inhibition, relying...
